Hepatitis C treatment guidelines Markets to 2019 - Market Shares, Strategies, and Forecasts Report Available Online By

Hepatitis C treatment guidelines Markets to 2019 - Market Shares, Strategies,
           and Forecasts Report Available Online By ResearchMoz.us

  PR Newswire

  ALBANY, New York, February 19, 2014

ALBANY, New York, February 19, 2014 /PRNewswire/ --

ResearchMoz.us includes new market research report " Hepatitis C Therapeutics
in Major Developed Markets to 2019 " to its huge collection of research

Researchmoz presents this most up-to-date research on Hepatitis C Therapeutics
in Major Developed Markets to 2019 (
). GBI Research, has released the pharma report - "Hepatitis C Therapeutics in
Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage
Pipeline to Transform Clinical and Commercial Landscape". The current
Hepatitis C treatment landscape consists of a combination of pegylated
interferon, ribavirin and, in patients infected with genotype 1 hepatitis C,
one of two direct-acting antiviral agents (DAAs). Products with these
mechanisms of action have performed strongly in the commercial setting, with
the market leader Incivek (a DAA) having reached blockbuster sales. However,
these products are very poorly tolerated and only moderately efficacious. The
approval of the DAA Sovaldi in December 2013 changed this, with a complete
viral clearance being achieved in close to 100% of patients and a much
improved adverse event profile compared to previous standards of therapy. In
patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be
administered with pegylated interferon. A number of products in the late-stage
pipeline, which promise to be even more efficacious and safe are anticipated
to enter the market over the forecast period, including several
interferon-free therapies for genotype 1-infected patients. As a result of
this, as well as an overall increase in the treated population, GBI Research
believes the global market has the potential to grow to a value of $18.6
billion by 2019, more than tripling the 2012 market value of $5.8 billion.


A brief introduction to hepatitis C, including the disease's pathogenesis,
risk factors and diagnosis, and detailed analyses of disease epidemiology and
treatment algorithms.

In-depth analysis of the major antiviral drugs used in the treatment of
hepatitis C, including analyses of their safety, efficacy, treatment patterns
and strengths/weaknesses. Includes a heat map that compares marketed drugs in
terms of safety and efficacy.

A comprehensive review of the pipeline for hepatitis C therapies, including
individual analysis of a number of late-stage pipeline drugs that are likely
to enter the market during the forecast period. The pipeline is analyzed by
phase distribution, molecule type and molecular target.

In-depth clinical trial enrolment, trial duration and program failure rate
analyses for each molecule type and mechanism of action. Additionally,
clinical trial endpoints and certain selection criteria are analyzed in great
depth. This section also includes an additional heat map regarding pipeline
products, and a direct cross-analysis against currently marketed products.

Multi-scenario forecast data of the market to 2019, which takes into account
the effects of the introduction of new drugs, the expiry of key patents on
current drugs and the changes in disease epidemiology across the key developed
markets: US, Canada, Japan, Germany, UK, France, Italy and Spain.

Discussion of the drivers and barriers for market growth.

Analysis of licensing and co-development deals occurring in the hepatitis C

Reasons to Buy

Understand the different types of hepatitis C therapies and how treatment
varies by genotype.

Understand the treatment algorithms and guidelines related to hepatitis C, how
they are anticipated to change during the forecast period and where
opportunities and unmet needs lie.

Understand the vast scope of the pipeline, including which molecule types and
mechanisms of action are most prominent.

Observe trends in clinical trial duration and size as clinical phase and
molecule type varies. Use the clinical trial failure rate analysis to assess
the risk profiles of current and/or future developmental programs for
hepatitis C therapeutics.

Observe the shift in clinical trial endpoints with each clinical Phase, and
use this data to potentially influence any future developmental programs.
Additionally, understand the trends in enrolment by patient genotype.

Assess the potential clinical and commercial impact of current late-stage
pipeline molecules and the points of opportunity which remain to be
capitalized upon.

Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures

2 Introduction 2.1 Signs and Symptoms 2.2 Etiology and Risk Factors 2.3
Pathophysiology 2.4 Epidemiology 2.4.1 US and Canada 2.4.2 Europe 2.4.3 Japan
2.4.4 Regional Prevalence of Hepatitis C Genotypes 2.5 Prognosis 2.6 Diagnosis
and Screening 2.7 Treatment 2.8 Treatment Algorithms

3 Marketed Products 3.1 Ribavirin 3.2 Pegasys (Peginterferon alfa 2a) and
PegIntron (Peginterferon alfa 2b) - Hoffmann La Roche and Merck & Co 3.2.1
Pegasys - Hoffmann La Roche 3.2.2 PegIntron - Merck & Co 3.3 Incivek
(telaprevir) - Vertex Pharmaceuticals and Janssen-Cilag 3.4 Victrelis
(boceprevir) - Merck & Co 3.5 Olysio (simeprevir) - Johnson and Johnson 3.6
Sovaldi (sofosbuvir) - Gilead Sciences 3.7 Heat Map for Marketed Products

Related & Recently Added Reports by Researchmoz.us to its store.

Ophthalmology Therapeutics in Major Developed Markets (
) GBI Research has released its pharma research, "Ophthalmology Therapeutics
in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline
to Trigger Shift in Treatment Paradigm to Combination Therapies", which
provides insights into two therapeutic indications in ophthalmology in Top
Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and
Canada. The report provides an in-depth analysis of the therapeutic
indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The
report provides an estimation of market size for 2012, along with market
forecast until 2019. It also covers disease epidemiology, treatment
algorithms, treatment patterns, in-depth analysis of the pipeline, and deal
analysis for these two ophthalmology indications.

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 (
) GBI Research has released its pharma report "Cystic Fibrosis Therapeutics in
Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards
Personalized Treatment and Market Growth." The value of the Cystic Fibrosis
(CF) market is expected to increase significantly in value over the forecast
period across the leading eight developed nations, from $695.6 million in 2012
to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate
(CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action
are the primary factor driving the growth of the value of the market. The
positive impact of new market entrants will offset the effects of key patent
losses during the forecast period.

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 (
) GBI Research has released its pharma report "Systemic Psoriasis Therapeutics
in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel
Pipeline Drugs to Drive Growth". The systemic psoriasis market is forecast to
grow substantially over the forecast period from $5.0 billion in 2013 to $10.4
billion in 2020, across the eight major markets. This growth will be driven by
a rising treatment population and the continued uptake of biologics. Biologics
will continue to drive market growth despite leading brands Enbrel
(etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent
protection in most of the major markets over the forecast period.

Gastrointestinal Therapeutics in Major Developed Markets to 2019 (
) GBI Research, the leading business intelligence provider, has released its
latest research, 'Gastrointestinal Therapeutics (Irritable Bowel Syndrome,
Ulcerative Colitis and Crohn's Disease) in Major Developed Markets', which
provides insights into three gastrointestinal therapeutic indications in the
major developed markets of the US, the UK, France, Germany, Italy, Spain,
Japan and Canada. The report provides an in-depth analysis of three
gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS),
Ulcerative Colitis (UC) and Crohn's Disease (CD).

Explorer More GBI Research Market Research Reports Publishing Reports at: 

About Us

ResearchMoz is the one stop online destination to find and buy market research
reports & Industry Analysis . We fulfill all your research needs spanning
across industry verticals with our huge collection of market research reports.
We provide our services to all sizes of organizations and across all industry
verticals and markets. Our Research Coordinators have in-depth knowledge of
reports as well as publishers and will assist you in making an informed
decision by giving you unbiased and deep insights on which reports will
satisfy your needs at the best price.

For More Information Kindly Contact: 90 Sate Street, Suite 700Albany, NY 12207
Website@ http://www.researchmoz.us/ Blog: http://usresearch.blogspot.com/
Blog: http://industryresearchnews.blogspot.com Email: sales@researchmoz.us
Tel: +1-518-618-1030USA - Canada Toll Free: 866-997-4948
Press spacebar to pause and continue. Press esc to stop.